BEYOND AIR, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.594 USD | -2.94% |
|
-5.39% | -69.39% |
| Jul. 01 | Beyond Air, Inc.(NasdaqCM:XAIR) dropped from Russell Small Cap Comp Value Index | CI |
| Jul. 01 | Beyond Air, Inc.(NasdaqCM:XAIR) dropped from Russell Small Cap Completeness Index | CI |
Financials (USD)
| Sales 2025 * | 9.67M | Sales 2026 * | 31.61M | Capitalization | 28.09M |
|---|---|---|---|---|---|
| Net income 2025 * | -44M | Net income 2026 * | -33M | EV / Sales 2025 * | 3.21 x |
| Net Debt 2025 * | 2.95M | Net cash position 2026 * | - | EV / Sales 2026 * | 0.89 x |
| P/E ratio 2025 * |
-0.53
x | P/E ratio 2026 * |
-0.69
x | Employees | 107 |
| Yield 2025 * |
-
| Yield 2026 * |
-
| Free-Float | 81.31% |
More Fundamentals
* Assessed data
More news
Latest transcript on Beyond Air, Inc.
More recommendations
More press releases
| 1 day | -2.94% | ||
| 1 week | -5.39% | ||
| Current month | +11.65% | ||
| 1 month | -48.73% | ||
| 3 months | -62.03% | ||
| 6 months | -66.86% | ||
| Current year | -69.39% |
1 week
0.54
0.64
1 month
0.541.49
Current year
0.542.17
1 year
0.544.24
3 years
0.5416.41
5 years
0.5416.41
10 years
0.5416.41
| Managers | Title | Age | Since |
|---|---|---|---|
Steven Lisi
CEO | Chief Executive Officer | 53 | 17-01-12 |
Douglas Larson
DFI | Director of Finance/CFO | 53 | 21-08-31 |
Amir Avniel
PSD | President | 50 | 17-01-12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ronald Bentsur
BRD | Director/Board Member | 58 | 15-07-31 |
William Forbes
BRD | Director/Board Member | 62 | 18-08-12 |
Erick Lucera
BRD | Director/Board Member | 57 | 17-08-09 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 32 M€ | +4.54% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-03 | 0.5999 | -1.98% | 691 238 |
| 24-07-02 | 0.612 | -3.79% | 737,077 |
| 24-07-01 | 0.6361 | +18.39% | 2,171,837 |
| 24-06-28 | 0.5373 | -7.38% | 4,974,015 |
| 24-06-27 | 0.5801 | -8.52% | 3,232,362 |
Delayed Quote Nasdaq, July 03, 2024 at 11:10 am EDT
More quotes
Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received United States Food and Drug Administration (FDA) approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. It is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19), and nontuberculous mycobacteria (NTM) among others. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Its approved product and active pipeline of product candidates include LungFit PH, LungFit PRO and LungFit GO.
Calendar
2024-08-07
- Q1 2025 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.612
USD
Average target price
5.875
USD
Spread / Average Target
+859.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -69.39% | 28.09M | |
| -6.80% | 180B | |
| -6.03% | 99.21B | |
| -6.21% | 66.25B | |
| -11.13% | 44.74B | |
| +7.97% | 43.82B | |
| +10.35% | 41.96B | |
| +11.39% | 28.98B | |
| +16.18% | 24.07B | |
| -9.29% | 23.5B |
- Stock Market
- Equities
- XAIR Stock
